Skip to content

Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD Patients

Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated Chronic Obstructive Pulmonary Disease Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01933984
Enrollment
51
Registered
2013-09-04
Start date
2013-08-31
Completion date
2019-01-31
Last updated
2020-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

Bronchodilator agents,, chronic obstructive pulmonary disease,, endotracheal intubation,, mechanical ventilator

Brief summary

This study evaluates whether individualized dosing schedule of inhaled bronchodilator is more effective than fixed dosing in reducing airway resistance of intubated COPD patients.

Detailed description

\*Study Design * This is an open-label, randomized controlled study comparing individualized versus fixed bronchodilator dosing schedule for patients with COPD with acute respiratory failure. \*Patients Enrollment * We will collect 100 patients just admitted to the intensive care unit of Changhua Christian Hospital (Changhua, Taiwan) due to COPD with acute respiratory failure.All participants will be randomly assigned to either group according to a computer-generated allocation sequence in block size of 4 patients. \*Airway Resistance (Raw) Determination * Enrolled patients will be ventilated by either AVEA (CareFusion, Yorba Linda, CA, USA),e500 (Newport Medical Instrument Inc. CA, USA) or Eivta 4 (Drager) ventilator. When evaluating Raw, the ventilator settings will be transiently switched to volume control mode with fixed tidal volume (500 ml) and constant flow (with a rate of 60 L/min). Plateau pressure is measured by manually controlled end-inspiratory pause12. Every effort will be exercised to avoid excessive airway secretion or patient agitation during measurement. Each measurement will be repeated three times with an interval of at lease 1 minute and calculate their average. Raw will be calculated by an equation of (peak inspiratory pressure - plateau pressure)/flow. After each measurement, the ventilator will soon be reverted to its usual settings. Raw will be routinely determined every 8 hours for 28 days if the ventilator is not discontinued. \*Technique of Metered Dose Inhaler (MDI) administration through endotracheal tube * The technique basically follows the recommendation of Dhand and Guntur. Airway secretions should be sucked out before drug administration. Heat moisture exchanger, but not humidifier, is removed. After shaking and warming MDI to hand temperature, the canister is connected to an AeroChamber HC MV spacer (Trudell Medical International, London, Canada) placed in the inspiratory limb of ventilator circuit 15 cm away from the endotracheal tube. Actuation is synchronized with the initiation of inspiration. Each actuation is at least 15 second apart. \*Personal Target Raw Determination * The target Raw of each patient should be determined within 72 hours after their admission to intensive care unit. After confirming no inhaled bronchodilator given in preceding 2 hours (for fenoterol) or 12 hours (for salmeterol/fluticasone), we will deliver 3 consecutive doses of 4 puffs, 8 puffs and 16 puffs of fenoterol MDI (100 mcg/puff, Berotec;Boehringer Ingelheim, Ingelheim, Germany) inhalation with each dose 15 minutes apart. The Raw measured 15 minutes later is assigned as this patient's personal target Raw. \*Bronchodilator Delivery Schedule * Each patient will routinely receive 4 puffs of 25 mcg salmeterol /250 mcg fluticasone (Seretide Evohaler 250; GlaxoSmithKline Inc. Evreux, France) every 12 hours until the discontinuation of ventilator. Each patient will also routinely receive 1 vial of Combivent (ipatropium bromide 0.5 mg and salbutamol sulfate 2.5 mg) every 6 hours and be injected with intravenous methylprednisolone 40mg every 8 hours in the initial 3 days.The use of short acting bronchodilator in an as-needed basis is not restricted. According to the Raw data determined every 8 hours, individualized dosing group will receive an additional 4 puffs of 25 mcg salmeterol /250 mcg fluticasone plus 4 puffs of fenoterol if the value is higher than personal target Raw (Once it coincides with regular dosing period of salmeterol/fluticasone, only fenoterol will be added). No such extra dose will be given to fixed dosing (control) group regardless of Raw value. \*Statistical Analysis * Student's t test will be used to compare ∆Raw of both groups. For the comparisons of other continuous variables without distribution normality, Wilcoxon rank sum test will be used. When comparing two categorical variables, Chi-square or Fisher's exact test will be used when appropriate. A P value of less than 0.05 is considered significant.

Interventions

Salmeterol/fluticasone (Seretide Evohaler) 4 puffs plus fenoterol (Berotec)(0.1mg/puff) 4 puffs inhalation when target airway resistance, measured every 8 hours, not met

Sponsors

Shin-hwar Wu
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* chronic obstructive pulmonary disease * acute respiratory failure under ventilator support for less than 72 hours * endotracheal tube inserted

Exclusion criteria

* confirmed asthma * Acute Physiology and Chronic Health Evaluation II score over 35 * a co-morbidity of septic shock

Design outcomes

Primary

MeasureTime frameDescription
∆Raw (the Difference Between Measured and Target Airway Resistance)Airway resistance will be recorded everyday. If a patient's ventilator was liberated less than 28 days, the day of liberation was the reported time frame. If the day of ventilator liberation was over 28 days, the 28th day was the reported time frame.The value can be expressed as relative deviation from target =(measured Raw - target Raw)/target Raw X100
Rapidity of ∆Raw ChangeAirway resistance will be recorded everyday. If a patient's ventilator was liberated less than 28 days, the day of liberation was the reported time frame. If the day of ventilator liberation was over 28 days, the 28th day was the reported time frame.The deviation of ∆Raw from the personal target, which was calculated as (measured Raw-target Raw)/target Raw multiplied by 100.

Secondary

MeasureTime frameDescription
Number of Episode of Nosocomial Pneumoniathe 28th day after enrollmentThe number of episodes of nosocomial pneumonia happened by day 28. And nosocomial pneumonia is a lower respiratory infection that was not incubating at the time of hospital admission and that presents clinically 2 or more days after hospitalization.
Number of Total Puff of Rescue Short-acting Bronchodilatorthe 28th day after enrollmentThe number of total puff of rescue short-acting bronchodilator.
Ventilator-free Days From Day 1 to 28From day 1 to day 28 after enrollmentVentilator-free days from day 1 to 28 after enrollment
Mortality Ratethe 180th day after enrollmentThe percentage of participants died at day 180.
Numbers of Episode of Drug-related Adverse EffectFrom day 1 to day 28 after enrollmentThe numbers of episode of drug-related adverse effect. Naranjo score should be over 4 to be considered drug-related adverse effect. Naranjo score range form 0 to 9, and the higher scores means a higher relationship with drug-related adverse effect.
The Participants of Breathing Without Assistance by Day 28the 28th day after enrollmentThe number of participants who breath without ventilator by day 28

Countries

China

Participant flow

Participants by arm

ArmCount
Individualized Dosing
* Ventilator support * Determining personal target airway resistance * Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent * Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days * Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days * Additional broncho-dilators inhalation: Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met (until ventilator discontinuation or the 28th day if ventilator-dependent)
26
Fixed Dosing
* Ventilator support * Determining personal target airway resistance * Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent * Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days * Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days * No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met
25
Total51

Baseline characteristics

CharacteristicIndividualized DosingFixed DosingTotal
Age, Continuous73.6 years
STANDARD_DEVIATION 13.3
77.9 years
STANDARD_DEVIATION 8.7
75.7 years
STANDARD_DEVIATION 11.3
Body Mass Index25.6 kg/m^2
STANDARD_DEVIATION 11.6
23.4 kg/m^2
STANDARD_DEVIATION 4.9
24.5 kg/m^2
STANDARD_DEVIATION 8.9
Race/Ethnicity, Customized
Asian
26 participants25 participants51 participants
Sex: Female, Male
Female
5 Participants2 Participants7 Participants
Sex: Female, Male
Male
21 Participants23 Participants44 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
9 / 2610 / 25
other
Total, other adverse events
0 / 260 / 25
serious
Total, serious adverse events
0 / 260 / 25

Outcome results

Primary

Rapidity of ∆Raw Change

The deviation of ∆Raw from the personal target, which was calculated as (measured Raw-target Raw)/target Raw multiplied by 100.

Time frame: Airway resistance will be recorded everyday. If a patient's ventilator was liberated less than 28 days, the day of liberation was the reported time frame. If the day of ventilator liberation was over 28 days, the 28th day was the reported time frame.

ArmMeasureValue (MEAN)Dispersion
Individualized DosingRapidity of ∆Raw Change-3 percentage of relative Raw deviationStandard Deviation 9.7
Fixed DosingRapidity of ∆Raw Change0.4 percentage of relative Raw deviationStandard Deviation 13.9
Primary

∆Raw (the Difference Between Measured and Target Airway Resistance)

The value can be expressed as relative deviation from target =(measured Raw - target Raw)/target Raw X100

Time frame: Airway resistance will be recorded everyday. If a patient's ventilator was liberated less than 28 days, the day of liberation was the reported time frame. If the day of ventilator liberation was over 28 days, the 28th day was the reported time frame.

Population: The deviation of Raw from the personal target, which was calculated as (measured Raw-target Raw)/target Raw.

ArmMeasureValue (MEAN)Dispersion
Individualized Dosing∆Raw (the Difference Between Measured and Target Airway Resistance)9 percentage of relative Raw deviationStandard Deviation 10
Fixed Dosing∆Raw (the Difference Between Measured and Target Airway Resistance)44 percentage of relative Raw deviationStandard Deviation 11
Secondary

Mortality Rate

The percentage of participants died at day 180.

Time frame: the 180th day after enrollment

ArmMeasureValue (NUMBER)
Individualized DosingMortality Rate35 percentage of participants
Fixed DosingMortality Rate40 percentage of participants
Secondary

Number of Episode of Nosocomial Pneumonia

The number of episodes of nosocomial pneumonia happened by day 28. And nosocomial pneumonia is a lower respiratory infection that was not incubating at the time of hospital admission and that presents clinically 2 or more days after hospitalization.

Time frame: the 28th day after enrollment

ArmMeasureValue (MEDIAN)Dispersion
Individualized DosingNumber of Episode of Nosocomial Pneumonia0 episodes of nosocomial pneumoniaStandard Deviation 0
Fixed DosingNumber of Episode of Nosocomial Pneumonia0 episodes of nosocomial pneumoniaStandard Deviation 0
Secondary

Number of Total Puff of Rescue Short-acting Bronchodilator

The number of total puff of rescue short-acting bronchodilator.

Time frame: the 28th day after enrollment

ArmMeasureValue (NUMBER)
Individualized DosingNumber of Total Puff of Rescue Short-acting Bronchodilator0 puffs
Fixed DosingNumber of Total Puff of Rescue Short-acting Bronchodilator0 puffs
Secondary

Numbers of Episode of Drug-related Adverse Effect

The numbers of episode of drug-related adverse effect. Naranjo score should be over 4 to be considered drug-related adverse effect. Naranjo score range form 0 to 9, and the higher scores means a higher relationship with drug-related adverse effect.

Time frame: From day 1 to day 28 after enrollment

ArmMeasureValue (MEDIAN)Dispersion
Individualized DosingNumbers of Episode of Drug-related Adverse Effect0 episodesStandard Deviation 0
Fixed DosingNumbers of Episode of Drug-related Adverse Effect0 episodesStandard Deviation 0
Secondary

The Participants of Breathing Without Assistance by Day 28

The number of participants who breath without ventilator by day 28

Time frame: the 28th day after enrollment

ArmMeasureValue (NUMBER)
Individualized DosingThe Participants of Breathing Without Assistance by Day 2819 the number of participants
Fixed DosingThe Participants of Breathing Without Assistance by Day 2822 the number of participants
Secondary

Ventilator-free Days From Day 1 to 28

Ventilator-free days from day 1 to 28 after enrollment

Time frame: From day 1 to day 28 after enrollment

ArmMeasureValue (NUMBER)
Individualized DosingVentilator-free Days From Day 1 to 2819 day
Fixed DosingVentilator-free Days From Day 1 to 2822 day

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026